Oncology drug review

Vogel, lauren
September 2011
CMAJ: Canadian Medical Association Journal;9/6/2011, Vol. 183 Issue 12, pE789
Academic Journal
The article reports that new submissions are accepted for the pan-Canadian Oncology Drug Review which began on July 13, 2011 in all provinces in Canada except Quebec.


Related Articles

  • FURTHER READING.  // PharmaWatch: Biotechnology;Feb2008, Vol. 7 Issue 2, p25 

    A list of reports and briefs that discusses biosimilar drugs is presented.

  • CORRECTION:.  // Hem/Onc Today;10/10/2011, Vol. 12 Issue 19, p5 

    A correction to the cover of the September 10, 2011 issue of "HemOnc Today," which featured the BRAF-inhibitor vemurafenib, is presented.

  • ONCOLOGY BRIEFS.  // Dermatology Times;Jul2003, Vol. 24 Issue 7, p35 

    Reports issues related to oncology as of July 2003. Approaches to advanced tumors; Development of drugs for cutaneous lymphoma.

  • Informing Canada's cancer drug funding decisions with scientific evidence and patient perspectives: the Pan-Canadian Oncology Drug Review. Hoch, J. S.; Sabharwal, M. // Current Oncology;Apr2013, Vol. 20 Issue 2, p121 

    The article presents questions and answers related to Canada's cancer drug funding decisions including body reviewing drugs, how its is possible for pan-Canadian Oncology Drug Review (pcodr) to recommend not paying for a drug and how do factors enter into the pcodr process.

  • Research & Markets: Biologicals in Oncology Drug Pipeline Update 2011.  // Biomedical Market Newsletter;3/14/2011, p118 

    The article reports on the update regarding developments on drugs used in oncology.

  • Oncology Dominates Personalized Medicines Development.  // Applied Clinical Trials;Jun2015, Vol. 24 Issue 6/7, p11 

    The article reports that according to the study by the Tufts Center for the Study of Drug Development, oncology and cancer related illness, due to their complex nature, dominate the medical research and personalized medicine product development sector.

  • IN BRIEF.  // Hem/Onc Today;7/10/2010, Vol. 10 Issue 13, p29 

    This section offers news briefs concerning oncology, including the efficacy of the CD19/CD3-bispecific antibody blinatumumab, and the capability of the BiTE antibody blinatumomab in inducing complete molecular remission.

  • COMPANY SPOTLIGHT - GlaxoSmithKline Plc.  // PharmaWatch: Cancer;July 2005, Vol. 4 Issue 7, p23 

    This article provides information about GlaxoSmithKline PLC. It is one of the top five pharmaceutical firms in the world. The company develops, manufactures and markets pharmaceuticals, vaccines, over-the-counter (OTC) medicines and health-related consumer products. The company's principal...

  • Encore Abstracts.  // Journal of Oncology Pharmacy Practice;Sep2007, Vol. 13 Issue 3, p173 

    The article lists the titles of abstracts on medical topics which include "Prophylaxis for chemotherapy-induced neutropenia: patterns of care in U.S. community oncology practices," by Cynthia Baker, Lyssa Friedman, and Eric Elkin; "Adherence to anemia treatment guidelines in U.S. community...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics